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Abstract 
 
The E7 protein of low risk human papillomavirus type 11 has been shown to interact with 
multiple proteins key to viral function, including pRb and other pocket proteins, in both the 
cytoplasm and the nucleus.  It has been previously demonstrated that high risk HPV16 E7 and 
low risk HPV11 E7 share a novel nuclear import pathway independent of karyopherin proteins 
but dependent on the small GTPase Ran (Angeline, et al., 2003; Knapp, et al., 2009; Piccioli, et 
al., 2010).  In this study, we continued the analysis of the nucleocytoplasmic transport of HPV11 
E7 in vivo through transient transfection assays in HeLa cells with EGFP-HPV11 E7 fusion 
constructs and mutagenesis of critical amino acids.   
We found that nuclear localization of HPV11 E7 is mediated by a nuclear localization 
signal located in the C-terminal domain (cNLS).  This cNLS contains a unique zinc-binding 
domain consisting of two copies of a Cys-X-X-Cys sequence motif separated by 29 amino acids.  
To examine the role of the zinc-binding domain in HPV11 E7’s nuclear localization mediated by 
the cNLS, we mutated cysteine residues in each of the two copies of the Cys-X-X-Cys motif.  
After transient transfection in HeLa cells, we analyzed the localization of the resultant EGFP-
11cE7 mutants and EGFP-11E7 mutants in comparison with the corresponding wild type 
proteins using confocal fluorescence microscopy.  We discovered that mutations of cysteine 
residues in the two Cys-X-X-Cys motifs which affect the zinc binding clearly disrupted the 
nuclear localization of the EGFP-11cE7 and EGFP-11E7 mutants.  These data suggest that the 
integrity of the zinc-binding domain is essential for the nuclear localization of HPV11 cE7 and 
HPV11 E7 mediated by the cNLS.  Analysis of the localization of an EGFP-11E732SS/AA mutant, 
which cannot be phosphorylated by CKII, in comparison with the EGFP-11E7 wild type, 
revealed that CKII phosphorylation is not required for the nuclear localization of HPV11 E7.  In 
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addition, we discovered that HPV11 E7 has a leucine-rich nuclear export signal (NES) located at 
the C-terminus (76IRQLQDLLL84) mediating the nuclear export of HPV11 E7 in a CRM1-
dependent manner.  We will continue our mutational-functional analysis to further examine the 
nucleocytoplasmic transport of the low risk human papillomavirus type 11 E7 oncoprotein. 
 
Abbreviations: 
 
HPV: human papillomavirus 
pRB: retinoblastoma protein 
NPC: nuclear pore complex 
Kap: karyopherin 
CKII: casein kinase II 
NLS: nuclear localization signal 
NES: nuclear export signal 
EGFP: enhanced green fluorescent protein 
HeLa: Henrietta Lacks, originator; HPV18+ cervical epithelial carcinoma cell line 
RJA: ratjadone A, CRM-1 inhibitor 
CRM-1: chromosome region maintenance 1 (exportin 1), export receptor 
HA: hemagglutinin 
FG: phenylalanine/glycine repeats 
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Introduction 
 
I. Human papillomaviruses 
 Human papillomaviruses (HPVs) are small, icosahedral, non-enveloped DNA tumor 
viruses with circular, double-stranded genomes approximately 8 kb in size (Longworth and 
Laimins, 2004).  Of the approximately 200 identified HPV types, over 30 are known to infect 
anogenital and oropharyngeal mucosal epithelial tissue (zur Hausen, 2000).   
 HPV types are divided into five genera according to their evolutionary relationships and 
are designated as alpha, beta, gamma, mu, and nu HPVs.  Gamma, mu, and nu papillomaviruses 
comprise approximately 10% of HPVs and are only rarely associated with cancer.  Instead, they 
are implicated in the development of benign cutaneous papillomas (Doorbar, 2006).  The alpha 
and beta genera encompass 90% of HPV types.  Beta HPVs, including types 5 and 8, have been 
linked to non-melanoma skin cancers, particularly squamous cell carcinomas, in 
immunocompromised patients and individuals with the genetic disorder epidermodysplasia 
verruciformis (Pfister, 2003).  Alpha HPVs infect the anogenital mucosa as well as the skin and 
include cutaneous, high risk, and low risk types, classifications that correspond to their 
association with cancer development (Doorbar, 2006).  Low-risk HPV types, the most common 
being 6 and 11, are associated with the formation of benign epithelial hyperplasias, including 
condyloma accuminata, or genital warts.  Those classified as high risk, particularly types 16, 18, 
31, and 45, show a marked propensity for malignant progression (Longworth and Laimins, 
2004). 
 
II. Human papillomaviruses and cancer 
 HPV is the most common sexually transmitted infection in the United States (Dunne, et 
al., 2007).  As of 2004, 24.5% of females between 14 and 19 years old and 44.8% of females 
between 20 and 24 years old in the United States were infected with HPV (Dunne, et al., 2007).  
HPV DNA has been identified in over 99% of cervical cancers.  Moreover, HPV16 and HPV18 
infection account for nearly 70% of these cases (Dunne, et al., 2007).  Cervical cancer is the 
second most common cancer in women worldwide after breast cancer, with 450,000 new cases 
diagnosed each year (Parkin, et al., 2002; Bodily and Laimins, 2010).  A compelling link 
between HPV and cancer has been established not only in cervical cancers, but also in vulval, 
penile, oropharyngeal, tonsillar, and skin cancers (zur Hausen, 2009).   
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 Approximately 90% of HPV infections clear without medical intervention within a few 
years (Dunne, et al., 2007).  However, persistent infection occurs in roughly 10% of cases when 
the viral genome integrates into the host cell genome.  The viral life cycle is intricately tied to the 
differentiation program in host cells (Moody and Laimins, 2010).  The virus interacts with the 
basal lamina of the host, gaining access through microabrasions in the tissue.  It then attaches to 
receptors on basal epithelium cells, thought to include integrin α6 and heparan sulfate 
proteoglycans, through interactions between the capsid protein L1 and these select moieties 
(Doorbar, 2006).  After viral uptake into the cell, productive infection is dependent on host-cell 
machinery and is carefully regulated by viral proteins. 
 Oncogenic progression begins only upon the aberrant integration of the E6 and E7 
oncogenes into the host genome, bypassing viral regulation by E2 and interfering with host cell-
cycle controls (Doorbar, 2006).  Though expression of E6 or E7 alone is not enough to fully 
transform normal epithelial cells, co-expression of E6 and E7 with the ras or fos oncogenes 
highly increases the risk of tumorigenesis (zur Hausen, 2000).  These two major transforming 
proteins play a key role by interfering with numerous proteins involved in the cell-cycle 
regulation of host cells.  
 
III. The E7 major transforming protein 
 The HPV E7 oncoprotein is an acidic, 98 amino acid long polypeptide.  It has a 38 amino 
acid long amino terminus in an extended conformation that contains a Retinoblastoma protein 
(pRb) binding domain and a casein kinase II (CKII) consensus phosphorylation site 
(McLaughlin-Drubin and Munger, 2008; Knapp, et al., 2009).  The highly ordered carboxyl 
terminus of E7, amino acids 39-98, includes a tightly folded zinc-binding domain, a nuclear 
localization signal (NLS), and a nuclear export signal (NES) (Angeline, et al., 2003, Knapp, et 
al., 2009; McLaughlin-Drubin and Munger, 2008).  It has been proposed that the cysteine rich C-
terminus is involved in E7 dimerization in vivo, though it has not been shown whether this 
dimerization is necessary for E7 function (Clemens, et al., 1995).   
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 The E7 oncoprotein has multiple molecular targets in the cell in both the nucleus and the 
cytoplasm.  E7 has been shown to bind and inactivate Retinoblastoma protein (pRb), a major 
modulator of cell-cycle progression, along with other pocket proteins such as p130 and p107 
(McLaughlin-Drubin and Munger, 2008).  Interestingly, high risk HPV16 E7 binds pRb ten 
times more efficiently than low risk HPV6 E7 due to a one amino acid change in the pRb binding 
site at residue 22, from aspartic acid in the high risk to glycine in the low risk (Heck, et al., 
1992).  E7 interferes with pRb activity within the cell by targeting the protein for proteosomal 
degradation, disrupting its regulation of E2F transcription factors and allowing the activation of 
proliferative pathways irrespective of host growth factors (McLaughlin-Drubin and Munger, 
2008; Doorbar, 2006).  As a result, cyclin production increases, driving the cell cycle forward.  
This outcome is compounded by E7’s interference with the cyclin-dependent kinase inhibitors 
p21 and p27 which further contributes to a proliferative phenotype in infected cells 
(McLaughlin-Drubin and Munger, 2008).  Interactions have also been recorded between E7 and 
p600, a novel microtubule-associated protein.  The proposed downregulation of p600 by E7 is 
thought to correlate with the prevention of anoikis in infected cells, allowing the perpetuation of 
a transformed phenotype (McLaughlin-Drubin and Munger, 2008).  The multiple interactions of 
E7 and proteins in both the nucleus and the cytoplasm indicate the importance of its function to 
viral activity in both compartments.  It is therefore critical that the pathways that mediate its 
trafficking are elucidated. 
 
Figure 1. Schematic representation of the HPV E7 oncoprotein and affected cellular processes 
(McLaughlin-Drubin and Munger, 2008). 
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Figure 2. Schematic representation of the NPC 
(Fahrenkrog, B. and Aebi, U., 2003). 
IV. Nuclear Import and Export 
 The nuclear pore complex (NPC) forms a semi-permeable, selective barrier between the 
cytoplasmic and nuclear compartments.  It is an approximately 50 MDa complex, 100 nm in 
diameter, comprised of rings of nucleoporin proteins spanning the nuclear membrane (Alber, et 
al., 2007).  Approximately 30 different kinds of nucleoporins are oriented according to an eight-
fold, radially symmetric arrangement 
(Sorokin, et al., 2007).  Additional 
nucleoporins extend into both the 
nuclear and cytoplasmic 
compartments.  Within the nucleus, 
these nucleoporins are arranged into a 
basket-like structure; in the 
cytoplasm, they form linear spokes 
that extend outward.  These extended 
nucleoporins form a channel that 
allows for the passive diffusion of 
smaller molecules and proteins and 
also provide sites of interaction for 
larger cargoes which may then be 
translocated through the NPC (Sorokin, et al,. 2007; Alber, et al., 2007).  The ability to passively 
diffuse is limited to cellular components of less than 40 kD, but when facilitated by cellular 
import and export factors, cargoes on the order of a few megadaltons can be trafficked efficiently 
through the NPC (Ribbeck and Gorlich, 2002).   
 Facilitated import and export of cargoes between the nucleus and cytoplasm is mediated 
by a variety of receptor proteins and adapters.  A family of proteins called karyopherins (Kaps) 
can bind nuclear localization signals (NLSs) and nuclear export signals (NESs) on a cargo 
protein directly or interact with cargo through an adapter Kap (Moroianu, 1999).  Characteristic 
of Kaps is the additional ability to interact with the small GTPase Ran in its GTP bound state 
(Moroianu, 1999).  The canonical import pathway involves the binding of a Kap, referred to as 
an importin, to a protein’s NLS.  The resultant complex is translocated though the NPC via 
interactions with nucleoporins and dissociates within the nucleus upon binding of the small 
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GTPase Ran in its GTP bound form (Moroianu, 1999).  Nuclear export occurs upon the binding 
of a Kap, known as an exportin, to the nuclear export signal (NES) of a protein as well as Ran-
GTPase in its GTP bound form within the nucleus (Pemberton and Paschal, 2005).  This 
receptor-cargo-Ran-GTP tertiary complex is then translocated through the NPC and dissociates 
in the cytoplasm upon the hydrolysis of Ran-GTP to Ran-GDP (Pemberton and Paschal, 2005).  
The accessory components of these pathways, including the import and export receptors, are then 
recycled to their original compartments. 
 
V. Nucleocytoplasmic transport of high risk HPV16 E7 and low risk HPV11 E7 
 It has been recently established that high risk HPV16 E7 enters the nucleus through a 
novel, Ran-dependent pathway, independent of Kap β1, Kap β2, or Kap α2/β1 heterodimers 
(Angeline, et al., 2003; Knapp et al., 2009).  This import is mediated via a C-terminal NLS as 
well as a hypothesized N-terminal NLS (Knapp, et al., 2009).  Interestingly, the C-terminal 
domain of HPV16 E7 contains both an NES and an NLS and ultimately presents a mostly 
cytoplasmic phenotype (Knapp, et al., 2009).  The C-terminal domain of HPV11 E7, however, 
displays a mostly nuclear phenotype (Piccioli, et al., 2010).  To begin the characterization of the 
nuclear import of HPV11 E7, it was noted that the highly ordered C-terminal domain of HPV11 
E7 includes a unique zinc-binding domain that encompasses both a previously observed NLS as 
well as a putative NES that shares distinct sequence homology with the NES of HPV16 E7 
(Knapp, et al., 2009).  The goals of this study include the characterization of the role of the zinc-
binding domain of HPV11 E7 in the protein’s nuclear import and export as well as the 
characterization of the putative leucine-rich NES of HPV11 E7. 
 
 
Materials and Methods 
 
Cell Culture 
 ATCC (American Type Culture Collection) HeLa cells, an HPV18+ cervical epithelial 
carcinoma cell line, were cultured in Dulbeccos Modified Eagle Medium (DMEM) with 10% 
heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin solution (5,000 units 
penicillin and 5 mg streptomycin per mL).  The cells were maintained at 37°C in 5% CO2. 
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Antibodies 
 A GFP-α-mouse antibody (Clontech, Inc.) and a HRP-conjugated goat-α-mouse antibody 
(Santa Cruz Biotechnology, Inc) were used. 
 
Generation of EGFP fusion plasmids with HPV11 E7 wild type, HPV11 E7 N- and C- 
terminal domains, and HPV11 E7 and HPV11 cE7 mutants 
 EGFP-tagged HPV11 E7 fusion constructs, including the full length protein and 
fragments with amino acids 1-38 and 39-98, were established in the expression plasmid pEGFP-
C1 (Clontech, Inc).  These constructs were generated by other members of the Moroianu Lab as 
follows: the pEGFP-C1 plasmid was double digested with EcoR1 and BamH1, run on a 0.7% 
agarose gel, and the digested vector was extracted using a QIAquick Gel Extraction Kit 
(Qiagen).  DNA fragments spanning the full length HPV11 E7 or the C-terminal domain (aa 39–
98) were amplified using PCR oligonucleotides that added EcoR1 and BamH1 restriction 
endonuclease sites.  The PCR products were digested with EcoR1 and BamH1 restriction 
enzymes and then ligated using T4 DNA ligase into the EcoR1 and BamH1 cloning sites of 
pEGFP-C1.  The EGFP-11E71–38 was generated using the QuikChange™ Site-Directed 
Mutagenesis Kit (Stratagene) with EGFP-11E7 as a template together with mutated primers to 
delete amino acids 39-98.  The EGFP tag is located at the N-terminus of all constructs (Piccioli, 
et al., 2010). 
Oligonucleotide primers were designed and optimized for each mutant (Sigma-Genosys).  
All primers were HPLC purified.  The EGFP-11cE7C58A, EGFP-11cE757CCC/AAA, EGFP-
11cE7C91A, EGFP-11cE7C91_ mutant plasmids were generated using the QuikChange™ Site-
Directed Mutagenesis Kit (Stratagene) with EGFP-11cE7 as a template together with the 
corresponding mutated primers.  The same mutations, with the exception of the C91_ mutant, 
were also introduced in the context of EGFP-11E7 using the corresponding mutated primers.  
Lastly, additional mutants, EGFP-11E7C58A/L79A and EGFP-11E7C58A/82LLL/AAA, EGFP-
11E7C91A/L79A, and EGFP-11E7C91A/82LLL/AAA, were generated in the context of either the EGFP-
11E7C58A or EGFP-11E7C91A mutant plasmid using the corresponding mutant primers.  The 
EGFP-11cE7C59A, EGFP-11cE7C59D, EGFP-11E7C59A, and EGFP-11E7C59D mutants were 
generated by Zeynep Onder, a member of the Moroianu Lab. 
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 The mutant fusion plasmids were transformed into XL1-blue competent cells.  Cultures 
were plated onto 45 ng/µL kanamycin-LB agar plates.  Colonies were transferred to 10 mL LB 
cultures with 1:1000 kanamycin and grown overnight at 37°C and 235 rpm.  Plasmids were 
extracted using a Quantum Prep® Plasmid MiniPrep kit (BioRad).  The purified mutant DNA 
was analyzed for size by agarose gel electrophoresis and the sequence was obtained by direct 
sequencing (Eurofins MWG).  Verified mutant plasmids were maintained as stock cultures with 
glycerol at -80°C. 
 
Purification of recombinant EGFP-E7 fusion plasmids 
 Plasmids stored in XL1 Blue E. coli cells, maintained as stock cultures at -80°C, were 
grown in 50mL of LB with 1:1000 kanamycin overnight at 37°C and 235 rpm.  The plasmids 
were then purified using a Quantum Prep® Plasmid MidiPrep kit (BioRad).  The plasmids were 
analyzed for appropriate molecular weight and purity using agarose gel electrophoresis.  The 
concentration of each plasmid was obtained using a NanoDropTM 2000 spectrophotometer 
(Thermo Scientific). 
 
Transfection assays and confocal fluorescence microscopy analysis 
 HeLa cells were grown on 12 mm poly-L-lysine-coated glass cover slips for 24 h prior to 
transfection until 50-70% confluent.  A mixture of 3µL FuGENE 6 reagent (Roche Applied 
Science) and 0.6 µg of plasmid DNA was added to 97µL DMEM and incubated at RT for 20 min 
to allow complex formation.  The cells were placed in 500µL DMEM and the DNA/FuGENE 
solution was added to the cells.  After 5 h, the media was switched to 500µL DMEM with 1% 
penicillin-streptomycin and 10% FBS (DMEM+).  After 24 h, the cells were washed with 1xPBS 
(pH 7.4) three times for 3 min each.  The cells were fixed in 3.7% formaldehyde in 1xPBS for 10 
min and washed an additional three times with 500µL 1xPBS for 3 min each.  The cover slips 
were mounted on glass slides using VectaSheild-DAPI Mounting Media with DAPI (Vector 
Labs) for the visualization of the cell nuclei.  The cover slips were sealed to the slides with clear 
nail polish.  The slides were kept covered at 4°C until analysis.  Detection of EGFP-fusion 
proteins was performed using a Leica TCS Sp5 broadband confocal microscope (Leica 
Microsystems), and pictures were taken using Leica LAS AF software (Leica Microsystems).  
Quantification of the intracellular phenotypes, defined as mostly nuclear, pancellular, or mostly 
cytoplasmic, was performed on all transfections.  Data from at least four experiments was 
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compiled for the quantitative analysis and the graphical representations display averages with 
standard deviation. 
 
Ratjadone A treatment of transfected cells 
 A 10 ng/mL solution of Ratjadone A (RJA) in DMEM+ was added to transfected cells at 
20 h post transfection for 4 h.  A parallel transfection received no RJA treatment, but instead 
received fresh DMEM+ at 20 h post transfection. 
 
Immunoblot assays of transfected cells 
 Transfected cells were transferred to SDS-PAGE buffer with 1% β-mercapatoethanol, 
lysed, boiled for 10 min at 100°C, and vortexed.  The samples were then subjected to SDS-
polyacrylamide gel electrophoresis.  Transfer to a nitrocellulose membrane was performed at 
60V in Tris-Glycine buffer for 60 min.  Ponceau staining was used to visualize the proteins on 
the membrane and confirm equivalent protein loading.  Samples were blocked in 5% nonfat milk 
in 1xPBS (pH 7.4) for 1 h at RT or overnight at 4°C.  They were then incubated at RT for 1 h in 
a 1:2000 GFP-α-goat antibody solution.  Samples underwent three 5 min washes in 1xPBS, and 
were then incubated for 30 min in a 1:1500 HRP-conjugated goat-α-mouse antibody solution.  
Detection was performed using an ECL Detection Kit (GE Healthcare) and exposure with X-ray 
film (Denville Scientific Inc.) was done using an XO-MAT developer (Kodak). 
 
 
Results 
 
Immunoblot analysis of HPV11 cE7, HPV11 E7, and mutant proteins 
 In order to ensure that the proteins expressed in HeLa cells during transfection assays 
were the appropriate molecular weight and not degraded in vivo, EGFP tagged HPV11 E7 wild 
types and mutant proteins were compared to an EGFP standard in an immunoblot analysis 
(Figures 4A and 4B).  After detection with an anti-GFP antibody, the EGFP standard (Figures 
4A and 4B, Lane 1), a 28kD protein, was compared to that of the HPV11 E7 wild type and 
mutant proteins.  All of the recombinant proteins ran at a higher molecular weight and did not 
show degradation.  This confirmed that the proteins detected during fluorescence microscopy 
were intact proteins. 
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Localization of wild type EGFP-11E7, EGFP-11cE7, and EGFP-11nE7 in vivo 
 The equilibrium localization of wild type HPV11 E7, the N-terminal region of HPV11 E7 
(aa 1-38), and the C-terminal region of HPV11 E7 (aa 39-98) were analyzed in transfection 
assays.  The full-length EGFP-11E7 and the C-terminal domain of EGFP-11E7 presented a 
mostly nuclear phenotype in HeLa cells (Figure 5A).  Approximately 80% of cells transfected 
with either EGFP-11E7 or EGFP-11cE7 showed the proteins localized to the nucleus, while the 
remaining cells had a pancellular localization (Figure 5B).  The N-terminal domain of EGFP-
11E7 was shown to have a pancellular phenotype in 70% of cells and a mostly cytoplasmic 
phenotype in approximately 30% of cells (Figure 5A; Figure 5B).  The similar localization to the 
nucleus of both the C-terminal region and the full-length HPV11 E7 suggests that the nuclear 
import of HPV11 E7 is mediated by a nuclear localization signal in the C-terminal domain 
(cNLS). 
 
Nuclear import of HPV11 E7 is not dependent on CKII phosphorylation 
 To investigate whether CKII phosphorylation is a factor in the nuclear localization of 
HPV11 E7, two serines at positions 32 and 33 known to participate in CKII phosphorylation 
were mutated to alanine, a non-polar amino acid that cannot participate in CKII phosphorylation  
(McLaughlin-Drubin and Munger, 2008).  There was no observed change in localization in the 
EGFP-11E732SS/AA phosphorylation deficient mutant as compared to the wild type EGFP-11E7 
protein (Figure 6): both localized to the nucleus in approximately 80% of transfected cells 
(Figure 5B).  Because the 32SS/AA mutation did not affect the nuclear localization of HPV11 E7, 
we conclude that the nuclear import of HPV11 E7 is not dependent on CKII phosphorylation. 
 
The integrity of the C-terminal zinc-binding domain of HPV11 E7 is necessary for its 
nuclear localization in vivo 
 HPV11 E7’s zinc binding domain provides a highly ordered structure for the protein’s C-
terminal region.  Four cysteine residues at positions 58, 61, 91, and 94 conjugate a Zn2+ ion 
between them in a planar conformation, and the intervening sequence is arranged in a helix-loop-
alpha conformation (McLaughlin-Drubin and Munger, 2008).  To determine whether the zinc-
binding ability of HPV11 E7 is necessary for its nuclear localization, we mutated different 
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cysteine residues involved in zinc-binding to alanine in the context of both HPV11 E7 and 
HPV11 cE7 (Figure 3A). 
 Mutations in the second Cys-X-X-Cys sequence motif of HPV11 cE7, specifically the 
cysteine residue at position 91 to alanine or a deletion of the final 8 amino acids of HPV11 E7, 
resulted in a marked change in its localization.  As compared to the mostly nuclear wild type, the 
C91A and C91_ HPV11 cE7 mutants were observed to be mostly cytoplasmic in over 90% of 
transfected cells (Figure 8B, panels B and C; Figure 8C).  The C91A mutation in the context of 
the HPV11 E7 full length protein also resulted in a similar change in the localization, becoming 
mostly cytoplasmic in greater than 90% of cells (Figure 7A, panel E; Figure 7B).  These results 
indicated that zinc-binding deficient mutants were unable to localize to the nucleus. 
 To further analyze the zinc-binding domain, mutations in the first Cys-X-X-Cys sequence 
motif were performed.  Initial mutants converting the cysteine at position 58 to alanine in both 
the HPV11 E7 and HPV11 cE7 also displayed diminished nuclear localization.  The majority of 
cells transfected with either EGFP-11E7C58A or EGFP-11cE7C58A displayed a pancellular 
phenotype in over 70% of cells (Figure 7B; Figure 8A, panel C; Figure 8C, data not shown).  
The remaining 30% of cells displayed a mostly cytoplasmic localization of the mutant protein 
(Figure 7B; Figure 8C).  This intermediate phenotype, less dramatic than that seen in the C91_ or 
C91A mutants, suggested to us that neighboring cysteines at positions 57 and 59 may have 
countered the loss of zinc-binding ability in the C58A mutant.  These neighboring cysteines may 
have then restored partial function to the cNLS, allowing localization of some EGFP-11E7C58A 
and EGFP-11cE7C58A to the nucleus. 
 A final mutant with all three cysteines at positions 57, 58, and 59 converted to alanine 
was generated to confirm this hypothesis (Figure 3A).  In both the context of the HPV11 cE7 and 
the HPV11 E7, the localization of this mutant was mostly cytoplasmic in over 90% of cells 
(Figure 8A, Panel E; Figure 7A, Panel C; Figure 8C; Figure 7B).  This dramatic phenotype was 
very similar to that seen in the C91A and C91_ mutants.  Whereas in the C58A mutant, adjacent 
cysteines could restore zinc binding, allowing the mutant to localize to the nucleus to a lesser 
degree, the triple cysteine to alanine mutant was not able to localize to the nucleus.  Given the 
decrease observed in the nuclear localization of all of the zinc-binding deficient mutants, the 
zinc-binding ability of HPV11 E7 is necessary for the nuclear localization of the protein.  These 
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data confirmed that the structural integrity of the zinc-binding domain of HPV11 E7 is required 
for the activity of its cNLS. 
 
A conserved cysteine residue at position 59 is involved in HPV11 E7’s nuclear localization
 Structural studies suggest that the conserved cysteine at position 59 is not directly 
involved in zinc-binding (Ohlenschlager, et al., 2006).  To investigate the role of the cysteine at 
position 59 in the nuclear localization of HPV11 E7, a mutation of this cysteine to alanine was 
performed in the context of the HPV11 cE7 and HPV11 E7.  This alteration resulted in a mostly 
pancellular distribution of the mutant protein (Figure 9A, Panels C and G) in comparison to the 
mostly nuclear wild type (Figure 9A, Panels A and E).  Approximately 80% of cells had a 
pancellular phenotype, while the remaining 20% displayed a mostly nuclear phenotype (Figure 
9B).   
 It is thought that the cNLS of HPV11 E7 may interact with the nuclear pore complex 
through low-affinity hydrophobic interactions with phenylalanine-glycine (FG) repeats in 
nucleoporins in order to translocate into the nucleus, as previously shown for nuclear import 
receptors (Piccioli, et al., 2010; Ribbeck and Gorlich, 2002).  The conversion of a cysteine 
residue to a polar, acidic residue, aspartic acid, would diminish these hydrophobic interactions.  
We generated C59D mutants in both the context of HPV11 cE7 and HPV11 E7, and in both 
cases, the phenotype observed was pancellular in over 90% of cells (Figure 9B).  These data 
indicated that the cysteine at position 59 is involved in the nuclear localization of HPV11 E7, as 
its removal reduced the nuclear localization of the mutant.   
 
The RJA nuclear export inhibitor partially restores the nuclear localization of the HPV11 
E7 and HPV11 cE7 C58A and C91A mutants 
 The major nuclear export receptor CRM1 has been shown to interact with leucine-rich 
NESs like those found in HPV16 E7 (Fornerod, et al., 1997; Knapp, et al., 2009).  To begin our 
analysis of the putative leucine-rich NES of HPV11 E7, we treated transfected cells with the 
CRM1 inhibitor RJA and analyzed the localization of cells given the drug in comparison to an 
untreated control.  The positive control, designated HPV16E7-NES, is a fusion of HPV16 E7 and 
the NES of HIV-1 Rev, a leucine-rich NES known to interact with CRM1 (Malim, et al., 1991; 
Fornerod, et al., 1997).  Wild type HPV16 E7 has a predominantly nuclear phenotype (Knapp, et 
al., 2009).  However, upon the addition of the HIV-1 Rev NES to the C-terminus of HPV16 E7, 
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the protein localizes to the cytoplasm in approximately 90% of transfected cells (this report, 
Figure 10B).  Treatment with RJA prompts in a change in the localization back to nuclear in over 
90% of transfected cells (this report, Figure 10B).   
 When cells transfected with EGFP-11E7 were treated with RJA, approximately 90% of 
the cells had a mostly nuclear phenotype (Figure 10A, Panels C and D; Figure 10B).  This was a 
slight increase from the untreated wild type, for which 80% of the cells had a mostly nuclear 
phenotype (Figure 10A, Panels A and B; Figure 10B).  Additionally, this pattern was also seen in 
transfections performed with the EGFP-11cE7.  Whereas the EGFP-11cE7 protein localizes to 
the nucleus in 80% of cells, treatment with RJA resulted in 90% of cells having a mostly nuclear 
phenotype (Figure 11A, Panels A-D; Figure 11B).  These data suggested that HPV11 E7 has a 
functional NES located in its C-terminal domain whose activity can be diminished through 
RJA’s inhibition of CRM1.   
 To further examine the nuclear export activity of HPV11 E7, we examined effect of RJA 
treatment on the behavior of two zinc-binding deficient mutants, C58A and C91A, in the context 
of both the HPV11 E7 and HPV11 cE7.  After treatment with RJA, cells transfected with the 
EGFP-11E7C91A mutant had a mostly nuclear phenotype in approximately 55% of cells, while the 
remaining cells had a pancellular phenotype (Figure 10A, Panels K and L; Figure 10B).  This 
was a dramatic change from the untreated EGFP-11E7C91A, which had a mostly cytoplasmic 
localization in 90% of transfected cells (Figure 10A, Panels I and J; Figure 10B).  Similarly, after 
treatment with RJA, the EGFP-11E7C58A also had a mostly nuclear phenotype in approximately 
55% of cells, while the remaining cells had a pancellular phenotype (Figure 10A, Panels G and 
H; Figure 10B).  This was a significant change from the untreated EGFP-11E7C58A, which was 
observed to have a mostly cytoplasmic phenotype in approximately 35% of cells, and a 
pancellular phenotype in the remaining cells (Figure 10A, Panels E and F; Figure 10B).  Overall, 
treatment with RJA partially restored the nuclear localization of both the EGFP-11E7C91A and the 
EGFP-11E7C58A zinc-binding deficient mutants. 
 EGFP-11cE7C58A and EGFP-11cE7C91A transfected cells, when treated with RJA, also 
showed a partial recovery of their nuclear localization, though to a lesser extent.  Cells 
transfected with the EGFP-11cE7C91A mutant in the presence of RJA had a mostly nuclear 
phenotype in approximately 10% of cells, a pancellular phenotype in approximately 75% of 
cells, while the remaining cells had a mostly cytoplasmic phenotype (Figure 11A, Panels K and 
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L; Figure 11B).  This represented a change from the phenotype of the untreated EGFP-
11cE7C91A, which was mostly cytoplasmic in over 90% of transfected cells (Figure 11A, Panels I 
and J; Figure 11B).  Treatment of the EGFP-11cE7C58A transfected cells with RJA also resulted 
in a change in the localization of the protein.  Treated cells had a mostly nuclear phenotype in 
approximately 15% of cells, a pancellular phenotype in approximately 80% of cells, while the 
remaining cells had a mostly cytoplasmic phenotype (Figure 11A, Panels G and H; Figure 11B).  
Untreated cells transfected with the EGFP-11cE7C58A had a pancellular localization in 
approximately 65% of cells and a mostly cytoplasmic localization in the remaining cells (Figure 
11A, Panels E and F; Figure 11B).  Though the effect of RJA on the behavior of the zinc-binding 
mutants C58A and C91A in the context of the HPV11 cE7 was less dramatic than the change 
observed in the HPV11 E7 mutants, there was nevertheless a partial restoration of the nuclear 
localization of both the EGFP-11cE7C91A and the EGFP-11cE7C58A after treatment with RJA.  
These data suggest that HPV11 E7 has a functional NES located in its C-terminal domain that 
interacts with CRM1 and whose activity can be partially inhibited by the CRM1 inhibitor RJA. 
 
Mutations of critical leucine residues in a potential cNES change the localization of the 
HPV11 E7 C58A and C91A mutants 
 Previous work in the Moroianu Lab has revealed that the C-terminus of HPV16 E7 
contains a leucine-rich NES (Knapp, et al., 2009).  This sequence, 76IRTLEDLLM84, is highly 
conserved in HPV11 E7, particularly in the hydrophobic leucine (I/V/F/M) residues.  In order to 
investigate the homologous sequence in HPV11 E7, 76IRQLQDLLL84, we mutated critical 
leucine residues, one at position 79 and three at positions 82-84, in the context of both the EGFP-
11E7C91A and EGFP-11E7C58A mutants (Figure 3B).  In order to ensure that the proteins 
expressed in HeLa cells during transfection assays were the appropriate molecular weight and 
not degraded in vivo, EGFP tagged HPV11 E7 wild type and mutant proteins were compared to 
an EGFP standard in an immunoblot analysis (Figure 12).  After detection with an anti-GFP 
antibody, the EGFP standard (Figure 12, Lane 1), a 28kD protein, was compared to that of the 
wild type HPV11 E7 and mutant proteins.  All of the recombinant proteins ran at a higher 
molecular weight and did not show degradation.  This confirmed that the proteins detected 
during fluorescence microscopy were intact proteins. 
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 Both the EGFP-11E7C91A/L79A and EGFP-11E7C91A/82LLL/AAA mutants displayed altered 
phenotypes in comparison to the EGFP-11E7C91A.  The EGFP-11E7C91A/L79A displayed a mostly 
nuclear phenotype in approximately 20% of cells, a pancellular phenotype in approximately 75% 
of cells, and a mostly cytoplasmic phenotype in the remaining cells (Figure 13A, Panels E and F; 
Figure 13B).  Similarly, the EGFP-11E7C91A/82LLL/AAA mutant also displayed a mostly nuclear 
phenotype in approximately 20% of cells, a pancellular phenotype in approximately 75% of 
cells, and a mostly cytoplasmic phenotype in the remaining cells (Figure 13A, Panels G and H; 
Figure 13B).  This was a distinct change from the phenotype of the EGFP-11E7C91A mutant, 
which had a mostly cytoplasmic phenotype in 90% of transfected cells (Figure 13A, Panels C 
and D; Figure 13B).   
 The EGFP-11E7C58A/L79A and EGFP-11E7C58A/82LLL/AAA mutants also displayed an altered 
phenotype in comparison to the EGFP-11E7C58A mutant.  The EGFP-11E7C58A mutant was 
mostly cytoplasmic in approximately 30% of cells and pancellular in the remaining 70% of cells.  
However, the EGFP-11E7C58A/L79A mutant localized to the nucleus in approximately 20% of 
cells, was pancellular in 75% of cells, and localized to the cytoplasm in the remaining 5% of 
cells (Figure 14A, Panels E and F; Figure 14B).  The EGFP-11E7C58A/82LLL/AAA mutant had a 
slightly different distribution, with approximately 10% of cells displaying a mostly nuclear 
phenotype, 85% of cells a pancellular phenotype, and the remaining cells a mostly cytoplasmic 
phenotype (Figure 14A, Panels G and H; Figure 14B).   
 Overall, these data indicate that mutations in the critical leucine residues partially 
restored the nuclear localization of the HPV11 E7 C58A and C91A mutants.  This suggests that 
the sequence 76IRQLQDLLL84 is, indeed, the NES of HPV11 E7 and can mediate its nuclear 
export. 
 
 
Discussion 
 
 HPV11 E7 has been shown to interact with multiple proteins key to viral function in both 
the cytoplasm and the nucleus, and its activity in both cellular compartments suggests an active 
trafficking pathway at work in infected cells.  It has been previously demonstrated that HPV16 
E7 and HPV11 E7 share a novel import pathway independent of Karyopherin proteins but 
dependent on the small GTPase Ran (Angeline, et al., 2003; Knapp, et al., 2009; Piccioli, et al., 
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2010).  Previous work in the Moroianu lab has suggested a possible nuclear import pathway for 
HPV11 E7 involving direct, low-affinity hydrophobic interactions with FG repeats in 
nucleoporins in a manner analogous to Kap import receptors (Piccioli, et al., 2010).  In this 
study, we continued the analysis of the nucleocytoplasmic transport of HPV11 E7 in vivo 
through the investigation of the role of HPV11 E7’s zinc-binding domain in its nuclear 
localization.  Additionally, we examined the role of a putative leucine-rich cNES in HPV11 E7’s 
nuclear export.   
 EGFP-tagged HPV11 E7 wild type and mutant proteins were used in transient 
transfection assays in HeLa cells.  An N-terminal EGFP tag was used for the fusion proteins 
instead of a smaller tag, like an HA tag, to ensure that the fusion proteins were of a sufficient 
molecular weight to prevent passive diffusion into or out of the nucleus.  Though both HPV11 
E7 and HPV11 cE7 are under the passive diffusion limit of the NPC, HPV11 E7 is known to 
dimerize in vivo through a region in its C-terminal domain (Clemens et al., 1995).  The resulting 
dimers, with their additional EGFP tags, are unable to undergo passive diffusion.  The nuclear 
phenotypes of the EGFP-HPV11 E7 proteins were clearly distinct from the uniformly pancellular 
phenotype of a 1xEGFP control that can passively diffuse into and out of the nucleus.  
Additionally, the use of an EGFP tag allowed the elimination of an additional immunostaining 
step. 
 The EGFP-tagged wild type HPV11 E7 full length and HPV11 cE7 fusion proteins were 
observed to localize strongly to the nucleus, suggesting the presence of a C-terminal NLS.  
However, HPV11 E7, like HPV16 E7, lacks a classical monopartite or bipartite basic NLS 
(Angeline, et al., 2003).  A CKII-phosphorylation deficient mutant HPV11 E7 was demonstrated 
to also have a mostly nuclear phenotype like the wild type, indicating that the nuclear import of 
HPV11 E7 is not dependent on CKII phosphorylation.  To examine the hypothesized C-terminal 
NLS of HPV11 E7, we focused on the zinc-binding domain of HPV11 E7, a highly conserved 
region located in the C-terminus of the protein.  Cysteine residues at position 58, 61, 91, and 94 
complex a Zn2+ ion between them, resulting in a highly ordered, tightly folded C-terminal region 
(McLaughlin-Drubin and Munger, 2008).  Mutant proteins with key cysteines converted to non-
polar alanine residues would be deficient in stabilizing the Zn2+ ion, which could disrupt the 
structural integrity of the region.   
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 These cysteine to alanine mutations, performed in the context of both HPV11 E7 full 
length and HPV11 cE7, were found to have a marked influence on the protein’s localization 
phenotype.  We observed dramatically decreased nuclear localization of the mutants in 
comparison to the wild type protein.  The complete or partial loss of nuclear localization upon 
the disruption of the zinc-binding domain of HPV11 E7 indicates that this domain functions as 
the NLS of HPV11 E7.  The tertiary structure of HPV11 E7’s C-terminal domain established 
upon zinc-binding likely presents key amino acids that interact with FG-nucleoporins and allow 
the import of HPV11 E7.  These data indicating that the zinc-binding domain of HPV11 E7 
functions as the NLS mediating its nuclear import and localization have been recently published 
(Piccioli, et al., 2010).  Interestingly, preliminary studies with the high risk HPV16 E7 also 
suggest that the zinc binding domain of HPV16 E7 is essential for its nuclear localization 
(Junona Moroianu and Jeremy Eberhard).   
 Additional analysis of the zinc-binding domain of HPV11 E7 examined the role of a 
conserved cysteine residue at position 59.  This cysteine is not directly involved in zinc-binding, 
though its proximity to the involved cysteine residue at position 58 may provide additional 
stabilization of the zinc ion in the C58A mutant.  Mutations to alanine and to aspartic acid in the 
context of both the HPV11 E7 full length and C-terminal domain both resulted in a diminished 
nuclear localization of the mutant proteins.  Interestingly, while a diminished nuclear localization 
was observed in the C59A and C59D mutants, we did not observe cells with a mostly 
cytoplasmic phenotype, which would have indicated a complete loss of nuclear localization.  
This continued nuclear localization of the mutant proteins was subtle; for the EGFP-11cE7C59A 
mutant as well as the EGFP-11E7C59D and EGFP-11cE7C59D mutants, only approximately 5% of 
cells displayed a mostly nuclear phenotype.  A slightly more marked nuclear phenotype was 
observed, however, in the EGFP-11E7C59A mutant, with approximately 20% of cells displaying a 
mostly nuclear phenotype (see Figure 9B).  These data are in contrast to the pattern observed in 
experiments with the zinc-binding deficient mutants, which displayed pancellular and mostly 
cytoplasmic phenotypes.  The partial maintenance of nuclear localization of the C59A and C59D 
mutants suggests some nuclear localization continues without cysteine 59.  Further analysis is 
needed to elucidate the role of cysteine 59 in the nuclear import of HPV11 E7. 
 In our examination of the nuclear export pathway of HPV11 E7 with the nuclear export 
inhibitor RJA, we observed an increase in the nuclear phenotype in cells for both the full length 
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and C-terminal wild type HPV11 E7.  Additionally, when cells transfected with the C58A and 
C91A zinc-binding deficient mutants in the context of both the full length HPV11 E7 and 
HPV11 cE7 were treated with RJA, we observed a partial recovery of nuclear localization of 
these mutants.  These data indicate that HPV11 E7 contains an active NES in the C-terminus of 
HPV11 E7 that interacts with CRM1 to mediate export to the cytoplasm.  Furthermore, the 
activity of HPV11 E7’s cNES can be partially inhibited by the CRM1 inhibitor RJA. 
 We hypothesized that a leucine-rich sequence found at the C-terminus of HPV11 E7 was 
the cNES of HPV11 E7.  This sequence, 76IRQLQDLLL84, shares a high degree of homology 
with a sequence of HPV16 E7, 76IRTLEDLLM84, which has been shown previously to be the 
cNES of HPV16 E7 (Knapp, et al., 2009).  Mutations of critical leucine residues at position 79 or 
82-84 converted to alanine disrupted the export activity of this region, but it is important to note 
that these mutations were introduced in the context of the zinc-binding deficient mutants C58A 
and C91A.  Mutations of solely these leucine residues in the wild type HPV11 E7 or HPV11 cE7 
would have been insufficient to indicate their involvement in the NES of HPV11 E7.  The wild 
type proteins already demonstrate a distinctly nuclear phenotype, and inhibition of the NES in 
the wild type background would have been difficult to quantify.  However, the C58A and C91A 
mutants had a consistent pancellular or mostly cytoplasmic phenotype, respectively.  A change in 
the phenotype back to mostly nuclear upon a secondary NES mutation could then be observed 
and measured.  We did observe a change in the phenotype of the C58A and C91A mutants in 
both the HPV11 E7 and HPV11 cE7 upon mutation of the leucine residues.  There was a clear 
increase in the nuclear localization of these leucine mutants performed in the context of the 
C58A and C91A mutants.  However, we did not observe a complete restoration to the mostly 
nuclear phenotype of the wild type protein.  It is possible that with the added zinc-binding 
mutation, the doubly mutated proteins may have had some problems with folding and thus 
diminished import into the nucleus, lessening the effect of the export-blocking mutations.  
However, given the mitigating effect on nuclear export by the leucine mutations as well as by 
RJA, we suggest that the sequence 76IRQLQDLLL84 is the NES of HPV11 E7. 
 Further work concerning the balance between the nuclear import and export of HPV11 
E7, and the ramifications of this equilibrium, will be extremely intriguing.  Though HPV11 E7 
has a mostly nuclear phenotype, there is a consistent, low level of protein maintained in the 
cytoplasm, ostensibly due to the protein’s interactions with cytoplasmic targets.  However, the 
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equilibrium distribution of HPV11 E7 is decidedly in favor of nuclear import.  Interestingly, this 
is not the case for the high risk HPV16 E7.  The HPV16 cE7 displays a mostly cytoplasmic 
phenotype even though this region contains both a cNLS and a NES, suggesting that either the 
cNLS is weaker than that of HPV11 E7 or the NES is stronger than that of HPV11 E7 (Knapp, et 
al., 2009).  The full length HPV16 E7 protein, though, does display a mostly nuclear phenotype 
like HPV11 E7 (Knapp, et al., 2009).  Continued investigation of the differences between the 
nucleocytoplasmic transport of high risk HPV16 E7 and low risk HPV11 E7 will be informative 
regarding intrinsic cellular mechanisms for nucleocytoplasmic transport.  Moreover, additional 
insights into the movement of the E7 oncoprotein within infected cells will be crucial for our 
understanding of HPV’s prodigious ability to infect and transform mammalian cells and 
contribute to carcinogenesis. 
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Figure 3A. Schematic representation of HPV11 E7 indicating the zinc-binding domain, the 
CKII phosphorylation sites, and the different mutations performed.  Blue: CKII 
phosphorylation deficient mutation; Green: zinc-binding domain mutations.
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Figure 3B. Schematic representation of HPV11 E7 indicating the zinc-binding domain, the 
CKII phosphorylation sites, the proposed cNES, and the different mutations performed.  
Green: zinc-binding domain mutations; pink: cNES mutations. 
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Figure 4A. Immunoblot analysis of EGFP-11cE7 and mutants used in transfection 
experiments.  Lane 1: EGFP; Lane 2: EGFP-11cE7; Lane 3: EGFP-11cE7C91A; Lane 4: EGFP-
11cE7C91_; Lane 5: EGFP-11cE7C58A; Lane 6: EGFP-11cE757CCC/AAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4B. Immunoblot analysis of EGFP-11E7 and mutants used in transfection 
experiments. Lane 1: EGFP; Lane 2: EGFP-11E7; Lane 3: EGFP-11E732SS/AA; Lane 4: EGFP-
11E757CCC/AAA; Lane 5: EGFP-11E7C91A 
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Figure 5A. EGFP-11E7 and EGFP-11E739-98 localize mostly to the nuclei of HeLa cells. 
HeLa cells were transfected with EGFP-11E7, EGFP-11nE7 and EGFP-11cE7 fusion plasmids 
as indicated in the figure and examined by fluorescence microscopy at 24 h post transfection. 
Panels A, C and E show the fluorescence of the EGFP and Panels B, D and F the DAPI staining 
of the nuclei. 
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Figure 5B. Quantitative analysis of the localization of EGFP fusions with HPV11 E7 full 
length and its N and C domains. The data from experiments using EGFP-11E7, EGFP-
11E732SS/AA, EGFP-11nE7, and EGFP-11cE7 plasmids have been used for quantitative analysis 
and the graphic representation of average with standard deviation. Mostly nuclear, blue bars; 
pancellular, red bars; cytoplasmic, yellow bars. 
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Figure 6. An HPV11 E7 variant deficient in CKII phosphorylation is mostly nuclear like 
the HPV11 E7 wild type. HeLa cells were transfected with either EGFP-11E7 wild type or 
EGFP-11E7SS/AA mutant and examined by fluorescence microscopy at 24 h post transfection.  
Panels A and C represent the fluorescence of the EGFP and panels B and D the DAPI staining of 
the nuclei.  
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Figure 7A. The C91A and 57CCC/AAA mutations led to cytoplasmic localization of HPV11 
E7 full length. HeLa cells were transfected with EGFP-11E7 (panels A and B), EGFP-
11E757CCC/AAA (panels C and D), and EGFP-11E7C91A (panels E and F) plasmids and examined 
by fluorescence microscopy at 24 h post transfection.  Panels A, C, and E represent the 
fluorescence of the EGFP and panels B, D, and F the DAPI staining of the nuclei.  Note the 
mostly nuclear localization of EGFP-11E7 wild type (panel A) and the cytoplasmic localization 
of EGFP-11E757CCC/AAA (panel C) and EGFP-11E7C91A (panel E).  
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Figure 7B. Quantitative analysis of the intracellular localization of C58A, 57CCC/AAA, and 
C91A mutants in comparison with the wild type EGFP-11E7. The data from experiments 
using EGFP-11E7, EGFP-11E7C58A, EGFP-11E757CCC/AAA, and EGFP-11E7C91A plasmids have 
been used for quantitative analysis and the graphic representation. Mostly nuclear, blue bars; 
pancellular, red bars; cytoplasmic, yellow bars. 
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Figure 8A. The effect of C58A and 57CCC/AAA mutations on the localization of EGFP-
11cE7.  HeLa cells were transfected with either EGFP-11cE7 wild type (panels A and B), 
EGFP-11cE7C58A (panels C and D), and EGFP-11cE757CCC/AAA (panels E and F) plasmids and 
examined by fluorescence microscopy at 24 h post transfection.  Panels A, C, and E represent 
the fluorescence of the EGFP and panels B, D, and F the DAPI staining of the nuclei. 
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Figure 8B. The EGFP-11cE7C91A and EGFP-11cE7C91_ mutants are localized mostly in the 
cytoplasm, in contrast with the mostly nuclear localization of the EGFP-11cE7 wild type. 
HeLa cells were transfected with either EGFP-11cE7 wild type (panels A and D), EGFP-
11cE7C91A (panels B and E), or EGFP-11cE7C91_ (panels C and F) plasmids and examined by 
fluorescence microscopy at 24 h post transfection. Panels A, B, and C represent the 
fluorescence of the EGFP and panels D, E, and F the DAPI staining of the nuclei. 
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Figure 8C. Quantitative analysis of the intracellular localization of C58A, 57CCC/AAA, 
and C91A mutants in comparison with the wild type EGFP-11cE7. The data from 
experiments using EGFP-11cE7, EGFP-11cE7C58A, EGFP-11cE757CCC/AAA, and EGFP-
11cE7C91A plasmids have been used for quantitative analysis and the graphic representation.  
Mostly nuclear, blue bars; pancellular, red bars; cytoplasmic, yellow bars. 
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Figure 9A. The effect of C59A mutation on the localization of EGFP-c11E7 and EGFP-
11E7. HeLa cells were transfected with EGFP-11cE7 (panels A and B), EGFP-11cE7C59A 
(panels C and D), EGFP-11E7 (panels E and F) and EGFP-11E7C59A (panels G and H) plasmids 
and examined by fluorescence microscopy at 24 h post transfection.  Panels A, C, E, and G 
represent the fluorescence of the EGFP and panels B, D, F, and H the DAPI staining of the 
nuclei. Note the mostly nuclear localization of EGFP-11cE7 and EGFP-11E7 wild type (panels 
A and E) and pancellular localization of the C59A mutants (panels C and G). [Data thanks to 
Zeynep Onder] 
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Figure 9B. Quantitative analysis of the intracellular localization of C59A and C59D 
mutants in comparison with the wild type EGFP-11E7 and EGFP-11cE7. The data from 
experiments using EGFP-11E7, EGFP-11cE7C59A, EGFP-11E759D, EGFP-11cE7, EGFP-
11cE7C59A, EGFP-11cE7C59D plasmids have been used for quantitative analysis and the graphic 
representation. Mostly nuclear, blue bars; pancellular, red bars; cytoplasmic, yellow bars. 
[Data thanks to Zeynep Onder] 
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Figure 10A. The RJA nuclear export inhibitor partially restores the nuclear localization of 
EGFP-11E7 C58A and C91A mutants. HeLa cells were transfected with either EGFP-11E7 
wild type (panels A-D), EGFP-11E7C58A (panels E-H), EGFP-11E7C91A (panels I-L), and EGFP-
16E7NES (panels M-P) plasmids in the absence of any drug or in the presence of RJA and 
examined by fluorescence microscopy at 24 h post transfection.  Panels A, C, E, G, I, K, M, and 
O represent the fluorescence of the EGFP and panels B, D, F, H, J, L, N, and P the DAPI 
staining of the nuclei. 
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Figure 10B. Quantitative analysis of the effect of RJA on the localization of the EGFP-11E7 
C58A and C91A mutants. The data from experiments using EGFP-11E7, EGFP-11E7C58A, 
EGFP-11E7C91A, and EGFP-16E7NES plasmids, with or without RJA treatment, have been used 
for quantitative analysis and the graphic representation.  Mostly nuclear, blue bars; pancellular, 
red bars; cytoplasmic, yellow bars. 
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Figure 11A. The RJA nuclear export inhibitor partially restores the nuclear localization of 
EGFP-11cE7 C58A and C91A mutants. HeLa cells were transfected with either EGFP-11cE7 
wild type (panels A-D), EGFP-11cE7C58A (panels E-H), EGFP-11cE7C91A (panels I-L), and 
EGFP-16E7NES (panels M-P) plasmids in the absence of any drug or in the presence of RJA and 
examined by fluorescence microscopy at 24 h post transfection. Panels A, C, E, G, I, K, M, and 
O represent the fluorescence of the EGFP and panels B, D, F, H, J, L, N, and P the DAPI 
staining of the nuclei.   
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Figure 11B. Quantitative analysis of the effect of RJA on the localization of EGFP-11cE7 
C58A and C91A mutants. The data from experiments using EGFP-11cE7, EGFP-11cE7C58A, 
EGFP-11cE7C91A, and EGFP-16E7NES plasmids, with or without RJA treatment, have been 
used for quantitative analysis and the graphic representation.  Mostly nuclear, blue bars; 
pancellular, red bars; cytoplasmic, yellow bars. 
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Figure 12. Immunoblot analysis of EGFP-11E7 and mutants used in transfection 
experiments.  Lane 1: EGFP; Lane 2: EGFP-11E7; Lane 3: EGFP-11E7C58A; Lane 4: EGFP-
11E7C58A/L79A; Lane 5: EGFP-11E7C58A/82LLL/AAA; Lane 6: EGFP-11E7C91A; Lane 7: EGFP-
11E7C91A/L79A; Lane 8: EGFP-11E7C91A/82LLL/AAA 
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Figure 13A. Mutations of critical leucine residues in a potential cNES change the 
localization of the EGFP-11E7 C91A mutant. HeLa cells were transfected with either EGFP-
11E7 wild type (panels A and B), EGFP-11E7C91A (panels C and D), EGFP-11E7C91A/L79A 
(panels E and F), and EGFP-11E7C91A/82LLL/AAA (panels G and H) plasmids and examined by 
fluorescence microscopy at 24 h post transfection.  Panels A, C, E, and G represent the 
fluorescence of the EGFP and panels B, D, F, and H the DAPI staining of the nuclei. 
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Figure 13B. Quantitative analysis of the effect of mutations of critical leucine residues in a 
potential cNES on the localization of the EGFP-11E7 C91A mutant. The data from 
experiments using EGFP-11E7, EGFP-11E7C91A, EGFP-11E7C91A/L79A, and EGFP-
11E7C91A/82LLL/AAA plasmids have been used for quantitative analysis and the graphic 
representation.  Mostly nuclear, blue bars; pancellular, red bars; cytoplasmic, yellow bars. 
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Figure 14A. Mutations of critical leucine residues in a potential cNES change the 
localization of the EGFP-11E7 C58A mutant. HeLa cells were transfected with either EGFP-
11E7 wild type (panels A and B), EGFP-11E7C58A (panels C and D), EGFP-11E7C58A/L79A 
(panels E and F), and EGFP-11E7C58A/82LLL/AAA (panels G and H) plasmids and examined by 
fluorescence microscopy at 24 h post transfection.  Panels A, C, E, and G represent the 
fluorescence of the EGFP and panels B, D, F, and H the DAPI staining of the nuclei.
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Figure 14B. Quantitative analysis of the effect of mutations of critical leucine residues in a 
potential cNES on the localization of the EGFP-11E7 C58A mutant. The data from 
experiments using EGFP-11E7, EGFP-11E7C58A, EGFP-11E7C58A/L79A, and EGFP-
11E7C58A/82LLL/AAA plasmids have been used for quantitative analysis and the graphic 
representation.  Mostly nuclear, blue bars; pancellular, red bars; cytoplasmic, yellow bars.
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